Introduction
Autosomal polycystic kidney disease (PKD) is the most common monogenic disorder [1] . In Europe, the annual incidence rate for end-stage renal disease (ESRD) due to autosomal-dominant PKD in men and women is 7.8 and 6.9 per million, respectively [2] . Data from the French dialysis registry (REIN) show that, among 8033 patients who started dialysis in 2008, 497 (6.2%) had PKD as a cause of ESRD [3] . Theoretically, PKD patients reaching ESRD can be treated either by peritoneal dialysis (PD) or haemodialysis. However, PKD is associated with a lower rate of PD utilization at dialysis initiation which emphasizes nephrologists concerns about PD success in this group of patients [4] . Indeed, one may argue that kidney enlargement due to renal cyst volume may jeopardize technique survival in PD patients. Because of the increased intra-peritoneal pressure, PKD patients on PD may experience more abdominal wall complications and peritoneal leaks than other patients [5, 6] . However, automated peritoneal dialysis (APD), which is nowadays widely used, can avoid high intra-peritoneal pressure [7] . In addition, most PKD patients on dialysis are transplanted at a greater rate than other patients, most probably because they are healthier [8] . Therefore, one may hypothesize that peritoneal dialysis is a suitable method for PKD patients starting renal replacement therapy, at least in a country where renal transplantation is available, and, further, where transfer to haemodialysis is possible. To our knowledge, there is no large-scale study to date aimed at evaluating the results of PD in PKD patients.
This study was carried out to assess whether PKD is associated with technique failure in ESRD patients starting peritoneal dialysis. This study was also conducted to evaluate the outcome of PKD patients on peritoneal dialysis in the modern era of PD.
Materials and methods

Study population
Using the database of the Registre de Dialyse Péritonéale de Langue Française (RDPLF), we identified all non-diabetic patients starting PD between 1 January 2002 and 31 December 2007 (end of the observation period: 31 December 2008) in metropolitan France or Belgium who were at least 18 years old at PD initiation. We excluded patients previously treated by PD, haemodialysis for >90 days or renal transplantation, leaving 4162 patients in the cohort.
Outcomes and censoring
We examined technique survival (permanent transfer to HD as outcome), patient survival (death as outcome), survival until transplantation and survival until first peritonitis episode. Patients experiencing outcomes other than the one of interest were censored for all analyses except for the competing-risk cumulative incidence curves which consider all outcomes simultaneously [9] .
Definition of PKD and other underlying nephropathies
Underlying nephropathy was defined according to reports by the treating centres to the RDPLF. We reclassified them into nine classes: glomerulonephritis, vascular nephropathy, nephroangiosclerosis, interstitial nephritis, uronephropathy, systemic diseases, miscellaneous, nephropathy from unknown origin and PKD.
Definition of covariates
We extracted sex, age and the Charlson comorbidity index (CCI) score upon starting PD and calculated a modified CCI by subtracting the age subscore. We calculated the type of PD and type of assistance at day 90 after PD initiation, imputing values at day 0 for patients with <90 days on PD (n = 406) and values immediately following day 90 for patients on short-term HD at this time (n = 7). In order to evaluate a possible effect of centre size, we calculated the mean number of adult patients on PD per day per centre over the study period and transformed this variable into three classes [10, 11] .
Statistical analysis
We first described patients with PKD and compared them with patients with other causes of ESRD, based on the full cohort (n = 4162) using frequencies and percentages for categorical variables and medians and interquartile ranges (IQR) for continuous variables, all of which had skewed distributions.
We drew unadjusted survival curves using the Kaplan-Meier method and cumulative incidence curves for each possible outcome, accounting for competing-risk events [10] . Curves show the time until 10% of patients remained in follow-up [12] .
We then explored the specific relationship between PKD and the outcomes (transfer to HD, death, transplantation, first peritonitis) by calculating hazard ratios (HR) and 95% confidence intervals (95% CI) with Cox regression models which, in the presence of competing risks, estimate covariate effects on cause-specific hazards. We also calculated incidence rate ratios (IRR), using data for all peritonitis episodes, by Poisson's generalized linear models (for peritonitis of any cause and of enteric origin separately). Enteric peritonitis was defined as that caused by micro-organisms known to colonize the gastrointestinal tract including Gram-negative organisms, Enterococcus, Streptococcus bovis and Candida spp. To account for dependencies in the data, all models included centre as a random effect and the Poisson models additionally included patients as a random effect clustered within centres [13] . To ensure on-data comparisons, we excluded centres without any PKD patients on PD (n = 350 patients in 35 centres) and non-PKD patients with a CCI greater than the maximum CCI for PKD patients (10 points) (n = 70). We then excluded patients with missing CCI data (n = 253) and unclear type of assistance at day 90 (n = 83), leaving 3406 patients (PKD n = 323, non-PKD n = 3083) for the models.
Our a priori confounders for all models were age, sex, CCI or modified CCI in models with age, and type of assistance at day 90 (all related to comorbidity and coping), and centre size (possibly related to patient comorbidity and service availability). We did not adjust on type of PD as we considered this an intermediate variable on the PKD-outcome pathways. We modelled age as a continuous variable except in the peritonitis models, where we used tertiles because of a possible U-shaped relationship identified during exploratory analyses. We modelled the CCI and modified CCI as categorical variables after regrouping patients with scores ≥7 or ≥5, respectively, into the highest categories. Technique survival models were stratified on the modified CCI, when in the model as a covariable, as it was unclear if it met the proportional hazards assumption (scaled Schoenfeld residual plots).
In the adjusted models, we simply included all potential confounders without undertaking a statistical variable selection procedure. However, we did check that removing each variable in turn from each model did not alter the width of the 95% CI around the PKD regression coefficient, suggesting that instability because of sparse cells in the full model was not an issue. We did not include interaction terms in the models as there were no a priori interactions of interest and power to explore interactions by signifi-cance testing was low. Analyses were done with R 2.10.1 (R Foundation for Statistical Computing, 2009), including the survival, cmprsk, coxme and lme4 packages.
Results
Patient characteristics
During the study period, there were 4374 non-diabetic patients who started peritoneal dialysis. Of these 4374 patients, 212 were excluded, leaving 4162 patients to be included in the analysis. Among 142 dialysis centres, 35 centres did not treat any PKD patients by PD during the period of interest. The centres were classified into three groups according to the mean number of all adult patients active on PD per day [< 20 (92/142 centres), 21-30 (27/ 142 centre) and >30 (23/142 centres)]. All centres where no PKD patients were treated by PD except one belonged to the group of centres with a mean number of active patients on PD per day under 20. There were 1623/4162 patients treated in the group of centres with <30 active patients per day, 1134/4162 patients in the group of centres 192) and nephropathy from unknown origin (680). Compared with other patients, PKD patients were younger, and therefore a lower CCI and so a lower modified CCI. As expected, PKD patients were more frequently treated by APD than other patients and were less frequently treated by assisted PD. Detailed information about baseline patient characteristics is provided in Table 1 .
Death-censored technique survival
On bivariate analysis, PKD nephropathy had no effect on technique survival (HR: 1.03, 95% CI: 0.81-1.31). In the multivariate analysis ( On the log-rank test, there was no difference between the PKD group and the non-PKD group regarding survival free of peritonitis. On the unadjusted Cox model, the HR for time to first episode of peritonitis (PKD vs non-PKD) was 0.84 (95% CI: 0.69-1.04). On multivariate analysis, only male gender was associated with time to first peritonitis (Table 3) .
On univariate analysis, PKD was not associated with a greater peritonitis incidence compared with non-PKD nephropathy (IRR: 0.82, 95% CI: 0.66-1.02). On multivariate analysis using the Poisson model, peritonitis was not associated with PKD, age, CCI, modified CCI, modality of assistance and centre size but only with patient gender (Table 4) . Subsequently, factors associated with enteric peritonitis were analysed separately. There was no association between PKD and enteric peritonitis in the unadjusted model (IRR: 1.00, 95% CI: 0.62-1.59). On multivariate analysis, PKD, patient age, gender, CCI, modified CCI, type of assistance and centre size were not associated with enteric peritonitis (Table 5) .
Patient survival on peritoneal dialysis
On bivariate analysis, PKD was associated with survival on dialysis (AHR: 0.35, 95% CI: 0.25-0.50). On multivariate analysis, survival was associated with PKD, patient age, modified CCI, modality of assistance in model 1 and by PKD, CCI and modality of assistance in model 2 (Table 6 ). Centre size was not associated with patient survival.
Cumulative incidence of each outcome treated as competing risks
Cumulative incidence for all of the possible outcomes on peritoneal dialysis for PKD patients and non-PKD patients is presented graphically in Figures 1 and 2 .
Discussion
It is generally accepted that abdominal wall complications of peritoneal dialysis negatively affect technique survival. Filling the peritoneal cavity during peritoneal dialysis leads to an increase in intra-abdominal pressure [14] . Whether high intra-peritoneal pressure reveals pre-existing hernias or provokes abdominal wall defects in peritoneal dialysis patients is controversial [15] . PD patients with hernias are exposed to a risk of bowel incarceration and strangulation, which may compromise PD continuation [16] . Abdominal wall hernias are common in PKD patients [17] . Because of the kidney enlargement, peritoneal pressure is probably increased during peritoneal dialysis in PKD patients compared with patients with small-sized kidneys. In support of this, PKD was identified as a risk factor for abdominal hernias and peritoneal leaks in a singlecentre study [5] . Therefore, it can be hypothesized that, because of abdominal complications, PKD is associated with a lower technique survival compared with other nephropathies. Increasing dialysate fill volume is often used in order to improve small solute clearance in an attempt to reach the PD adequacy criterion [18] . Abdominal discomfort due to the higher fill volume may also negatively affect technique survival especially in PKD patients. Another reason for technique failure in PKD patients on PD could be the need to perform nephrectomy before renal transplantation when kidney size can compromise the surgical transplant procedure [19] . After nephrectomy, patients may experience peritoneal leaks. In addition, nephrectomy also negatively affects residual renal function. In our study, having PKD as a cause of ESRD was not associated with peritoneal dialysis technique failure. It is important to notice that PKD patients were more frequently treated by APD than other patients. This could be explained by the younger age of PKD patients and/or by the medical decision to use APD to reduce high intra-peritoneal pressure. The use of APD may prevent abdominal wall complications in PKD patients. On the other hand, one may argue that PKD patients on PD were selected for peritoneal dialysis based on their kidney volume. Our results are consistent with the results of one recent study where PKD patients were matched with non-diabetic patients of the same age and gender with small-sized kidneys [20] . Even though patients included in the study were treated by PD between 1994 and 2005, only 18.5% of the PKD patients were treated by APD. Despite the low rate of APD utilization in PKD patients, there was no difference between the PKD group and the control group regarding the rate of abdominal complication and peritoneal leak. However, there were no data provided about the fill volume used in the two groups. The fact that PKD was not associated with technique failure in our study needs to be interpreted with caution. Indeed, one should keep in mind that PKD patients may have been selected by nephrologists for peritoneal dialysis based on several factors which may influence technique survival. Further studies designed to compare the outcome of PKD patients on haemodialysis with the outcome of PKD patients on PD are indeed necessary.
Even though the subject is still a matter of debate; patients with PKD have been reported to have a greater incidence of diverticulosis compared with the general population [21, 22] . Consequently, it is commonly believed that PKD patients on peritoneal dialysis are overexposed to enteric peritonitis compared with other patients. Although this finding needs confirmation, it has been found recently that intra-peritoneal pressure higher than 14 cm of H 2 O might be associated with a higher incidence of enteric peritonitis [23] . PKD was not associated with a higher incidence of peritoneal infection in our study. In addition, when analysed separately, enteric peritonitis incidence was not statistically greater in the PKD group than that observed in the control group. But it is important to notice that, because of the sample size, we cannot fully exclude an association between PKD and enteric peritonitis. Our findings are consistent with the results of the study of Pandya et al. who retrospectively compared 30 PKD patients with 505 non-PKD patients [24] . Neither peritonitis incidence nor Gram-negative peritonitis incidence was higher in the PKD group compared with the control group in this study. Also, survival free of peritonitis was not significantly different between the PKD group and the smallsized kidney group in the study of Kumar et al. [20] .
When studying technique failure, one should keep in mind that death and transplantation are competing events for transfer to HD in the sense that death or transplantation prevents us from being able to observe any subsequent transfer to HD which would have otherwise occurred [25] . In our study, transplantation was the main reason for stopping peritoneal dialysis in PKD patients whereas patient death was the main cause of PD cessation in other patients. This different pattern between PKD and other patients is hidden when using the Kaplan-Meier method to summarize survival probabilities because this method treats death and transplantation as censored events and therefore does not show the importance of these other outcomes. However, the competing risk cumulative incidence estimates suggest that peritoneal dialysis is a suitable method to treat PKD patients in a medical care system where transplantation is available and times on the waiting list before transplantation are comparable to those in France. Nevertheless, a study comparing the outcome of PKD patients on haemodialysis and on peritoneal dialysis is required to confirm this assumption.
Despite extra-renal manifestations of PKD such as liver cysts, intracranial aneurysms, cardiac valvular disease and diverticulosis, survival on dialysis of PKD patients is longer than that of general dialysis patients [21] . It has been shown recently that having PKD is a protective factor for death after renal transplantation [26] . Even after adjustment for confounding variables and despite the exclusion of diabetics from the study population, PKD patients had a lower risk of death than other patients in our study. Residual confounding factors which were not captured in the French Peritoneal Dialysis Registry or biased in relation to the physician's selection of PKD patients with particular profiles for PD may explain this finding. Because transplantation was the main reason for stopping peritoneal dialysis in the PKD group, one may argue that PKD patients on PD are healthier. It could also reflect the effect of the predialysis care on the outcome of PKD patients on peritoneal dialysis. Because of the familial nature of the disease, PKD patients may have been followed earlier in the predialysis clinic. Therefore, it can be hypothesized that the rate of unplanned dialysis initiation is lower in PKD patients and that PKD patients were prepared earlier for renal transplantation.
In conclusion, our study shows that at least a subgroup of PKD patients with ESRD can be treated by peritoneal dialysis. PKD patients are exposed neither to greater risk of technique failure risk nor to higher risk of peritonitis than non-diabetic dialysis patients in a health care system where renal transplantation is available.
